Alternate first-line treatments – triple versus dual ARV therapy
The biggest driver of change in the approach to first-line therapy has been the advent of dolutegravir, an integrase inhibitor, which has a high barrier to resistance
You will learn:
• Reasons for seeking alternative first-line antiretroviral (ARV) treatment regimens
• Current evidence on the robustness of dolutegravir (DTG) as part of first-line or second-line triple ARV therapy, and when used as monotherapy
• Current evidence on the efficacy and safety of two-drug regimens initiated as first-line therapy
• Current evidence on the efficacy and safety of switching the patient who is virally suppressed using a three-drug regimen to a two-drug regimen
To access this module, please register or login: